Skip to main content

Table 2 Achievement of Clinical Inactive Disease (CID) off Glucocorticoids (GC) in Non-Biologic and Biologic initiated patients (primary endpoint), as well as in the 4 Consensus Treatment Plan (CTP) groups

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

 

Biologic grouping

Patient Status at Month 9

Total N = 30

Gluco-corticoids N = 2

Methotrex-ate N = 6

IL1ia N = 12

IL6ia N = 10

p-value

Non-Biologic CTP N = 8

Biologic CTP N = 22

p-value

CID

13/30 (43.3%)

0/2

2/6 (33.3%)

5/12 (41.7%)

6/10 (60.0%)

0.549

2/8 (25.0%)

11/22 (50.0%)

0.407

Off GC

20/30 (66.7%)

1/2 (50.0%)

1/6 (16.7%)

10/12 (83.3%)

8/10 (80.0%)

0.019

2/8 (25.0%)

18/22 (81.8%)

0.007

CID off GC

11/30 (36.7%)

0/2

0/6

5/12 (41.7%)

6/10 (60.0%)

0.079

0/8

11/22 (50.0%)

0.014

CID off GC and no CTP change

8/30 (26.7%)

0/2

0/6

3/12 (25.0%)

5/10 (50.0%)

0.168

0/8

8/22 (36.4%)

0.071

  1. Also shown are all patients who achieved CID (regardless of GC), all patients who were off GC, and all patients who achieved CID off GC and did not change their CTP treatments, at 9 months. Patients lost to follow-up were considered treatment failures
  2. aIL1i: IL-1 inhibitor; IL6i: IL-6 inhibitor
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096